Literature DB >> 34229838

Moderate Alcoholic Hepatitis.

Ana Clemente-Sánchez1, Aline Oliveira-Mello2, Ramón Bataller3.   

Abstract

The natural history of moderate alcoholic hepatitis (AH) is not well known. It is a frequent disease with a probable underestimated incidence compared with its severe form. Among the different prognostic scores predicting short-term mortality in AH, MELD seems to be the most accurate. The mortality of moderate AH is 3% to 7% in the short to medium term and 13% to 20% at 1 year, mainly because of liver-related complications, including severe infections. Long-term abstinence is the main goal of the treatment. There is still need for the development of new therapies for AH, including the less severe forms.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abstinence; Alcoholic hepatitis; MELD; Moderate; Nonsevere; Survival

Mesh:

Year:  2021        PMID: 34229838      PMCID: PMC8757441          DOI: 10.1016/j.cld.2021.03.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.265


  60 in total

1.  Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].

Authors: 
Journal:  J Hepatol       Date:  2018-08-29       Impact factor: 25.083

2.  An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.

Authors:  Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2020-04-27       Impact factor: 17.425

3.  Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.

Authors:  Carolin Lackner; Walter Spindelboeck; Johannes Haybaeck; Philipp Douschan; Florian Rainer; Luigi Terracciano; Josef Haas; Andrea Berghold; Ramon Bataller; Rudolf E Stauber
Journal:  J Hepatol       Date:  2016-11-25       Impact factor: 25.083

4.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis.

Authors:  D Rincon; O Lo Iacono; C Ripoll; J Gomez-Camarero; M Salcedo; M V Catalina; A Hernando; G Clemente; A Matilla; O Nuñez; R Bañares
Journal:  Aliment Pharmacol Ther       Date:  2007-04-01       Impact factor: 8.171

6.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

7.  Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes.

Authors:  Jonathan R Potts; Mark R Howard; Sumita Verma
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-06       Impact factor: 2.566

Review 8.  Alcoholic liver disease: pathogenesis and new targets for therapy.

Authors:  José Altamirano; Ramón Bataller
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-09       Impact factor: 46.802

Review 9.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

10.  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.

Authors:  Giovanni Addolorato; Lorenzo Leggio; Anna Ferrulli; Silvia Cardone; Luisa Vonghia; Antonio Mirijello; Ludovico Abenavoli; Cristina D'Angelo; Fabio Caputo; Antonella Zambon; Paul S Haber; Giovanni Gasbarrini
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.